New data from drug research expected in autumn

Basle, Frankfurt The search for a drug to combat the treacherous Alzheimer’s disease is a history of failure. Despite decades of research and billions in investments, there is still no active substance that can stop the disease, let alone cure it.

Alzheimer’s affects two thirds of all dementia diseases – worldwide, soon 40 million patients and their relatives are waiting for a breakthrough in research. On Wednesday, World Alzheimer’s Day, they draw attention to their difficult situation with many activities.

This fall, however, a crucial question in Alzheimer’s research could be answered: namely, whether the removal of certain protein deposits in the brain, the so-called amyloid plaques, is the right approach in the fight against the destructive brain disease.

Because important study data are expected in the next few weeks from three active ingredients that follow this approach. All three are monoclonal antibodies, i.e. protein structures that bind to the so-called beta-amyloids in the brain.